S
MLTX icon

SignatureFD’s MoonLake Immunotherapeutics MLTX Stock Holding History

SignatureFD’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.2K Sell
1,962
-305
-13% -$5.53K ﹤0.01% 2028
2026
Q1 		$42.3K Buy
2,267
+853
+60% +$14.1K ﹤0.01% 1821
2025
Q4 		$18.6K Buy
1,414
+1,403
+12,755% +$16.6K ﹤0.01% 2154
2025
Q3 		$79 Hold
11
– – ﹤0.01% 3326
2025
Q2 		$519 Buy
+11
New +$448 ﹤0.01% 3102

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SignatureFD's MLTX Position: Q2 2026 in Review

SignatureFD reduced its MoonLake Immunotherapeutics (MLTX) stake by 13% in Q2 2026, selling an estimated $5.53K and leaving 1,962 shares worth $38.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2028.

SignatureFD first reported a position in MLTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $42.3K in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • SignatureFD held 1,962 shares of MoonLake Immunotherapeutics worth $38.2K as of Q2 2026.
  • SignatureFD sold 305 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $5.53K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2028 holding.
  • SignatureFD first reported a position in MoonLake Immunotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • SignatureFD's MoonLake Immunotherapeutics position peaked at $42.3K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.